ANDA 212103, held by Cadila Pharms Ltd. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 212103 (Atorvastatin Calcium), held by Cadila Pharms Ltd, was first approved by FDA on Oct 16, 2023, with 1 approved supplement and 0 published complete response letters.
Atorvastatin Calcium tablets are indicated:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 16, 2023 | Original application | Approved | None posted |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Discontinued |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Discontinued |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Discontinued |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Discontinued |
| Aug 30, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 16, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters